GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noile-Immune Biotech Inc (TSE:4893) » Definitions » Current Accrued Expense

Noile-Immune Biotech (TSE:4893) Current Accrued Expense : 円0.0 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Noile-Immune Biotech Current Accrued Expense?

Noile-Immune Biotech's Current Accrued Expense for the quarter that ended in Mar. 2024 was 円0.0 Mil.


Noile-Immune Biotech Current Accrued Expense Historical Data

The historical data trend for Noile-Immune Biotech's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noile-Immune Biotech Current Accrued Expense Chart

Noile-Immune Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Current Accrued Expense
- - - -

Noile-Immune Biotech Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only - - - - -

Noile-Immune Biotech Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Noile-Immune Biotech Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Noile-Immune Biotech's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Noile-Immune Biotech (TSE:4893) Business Description

Traded in Other Exchanges
N/A
Address
2-12-10 Shiba-Daimon, Minato-ku, Tokyo, JPN, 105-0012
Noile-Immune Biotech Inc is engaged in the development of novel cancer immunotherapy including CAR-T cell therapy.

Noile-Immune Biotech (TSE:4893) Headlines

No Headlines